The controversy surrounding the skyrocketing costs of Mylan's EpiPens, medication that counteracts potentially deadly allergic reactions, is "a product of their own success," according to a Wall Street Journal reporter on the pharma beat. "For a long time, this wasn't a product that many people knew about or wanted and it's really a credit to Mylan for making it into a brand with a name that is as well-recognized and highly sought as Band-Aids," Jonathan Rockoff said on Friday's MetroNews "Talkline."